<DOC>
	<DOCNO>NCT01493154</DOCNO>
	<brief_summary>This study test safety HPV DNA vaccine inject muscle use electroporation device ( TriGridTM Delivery System make Ichor Medical Systems ) , test ability vaccine help body 's immune system recognize HPV-infected associated cancer cell . In addition give vaccine use electroporation device , give vaccine combination immunomodulatory agent enhance immune response HPV-infected associate cancer cell .</brief_summary>
	<brief_title>Safety Study HPV DNA Vaccine Treat Head Neck Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Detox adjuvant</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis squamous cell carcinoma head neck unknown primary level II/III ( jugulodigastric ) nodal involvement ( find previous study result subclinical oropharyngeal carcinoma ) . 2 . Head neck cancer patient document HPV16 DNA within tumor determine situ hybridization eligible study . 3 . Freshfrozen paraffinembedded material must available situ hybridization test HPV16 DNA . 4 . Staging criterion establish American Joint Committee Clinical Investigation ( AJCC , Fifth Edition , 1997 ) Stage III ( T13N1M0 , T3N0M0 ) IV ( T14N2M0 , T4N01M0 ) disease . 5 . Age ≥ 18 year 6 . Life expectancy great 4 month . 7 . Baseline Eastern Cooperative Oncology Group performance status 0 , 1 time multimodality treatment administration . 9 . Patients must adequate organ function time enrollment define follow parameter : white blood cell count &gt; 3,000 lymphocyte number &gt; 500 absolute neutrophil count &gt; 1,000 platelet &gt; 90,000 hemoglobulin &gt; 9 total bilirubin &lt; 3 X institutional limit normal AST ( SGOT ) /ALT ( SGPT ) &lt; 3 X institutional limit normal creatinine &lt; 2.5X institutional limit normal 1 . Diagnosis immunosuppression prolong , active use immunosuppressive medication steroid . 2 . Prior enrollment vaccine study past 24 month . 3 . Presence uncontrolled concurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement . 4 . Presence history autoimmune disease multiple sclerosis , exclusive history thyroiditis , psoriasis , inflammatory bowel disease , Sjogren 's syndrome . 5 . Pregnancy breast feed . Pregnancy define female subject reproductive potential [ define girl reach menarche woman postmenopausal least 24 consecutive month , i.e. , menses within precede 24 month , undergone surgical sterilization ( e.g. , hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) ] must negative serum hcg test within 3 day prior study entry . 6 . History prior malignancy permit patient disease free ≥ 5 year , however individual completely resect basal cell squamous cell carcinoma skin within interval may enrol . 7 . Inability understand unwillingness sign inform consent document . 8 . Patients history arterial venous thrombosis . 9 . Patients nonhealed wound . 10 . Patients chronic infection history Hepatitis B , Hepatitis C , HIV infection determine serology test obtain eligibility screening . 11 . Current use electronic stimulation device , cardiac demand pacemaker , automatic implantable cardiac defibrillator , nerve stimulators , deep brain stimulators . 12 . History , document EKG within 30 day study eligibility screening , cardiac arrhythmia palpitation [ e.g. , supraventricular tachycardia , atrial fibrillation , frequent ectopy , sinus bradycardia ( i.e. , &lt; 50 beat per minute exam ) ] prior study entry . NOTE : Sinus arrhythmia exclude . 13 . History syncope fainting episode within 1 year study entry . 14 . Seizure disorder history prior seizure . 15 . Presence surgical traumatic metal implant site administration ( deltoid muscle ) . 16 . Bleeding disorder contraindication intramuscular injection . 17 . A skinfold measurement cutaneous subcutaneous tissue exceed 40mm one eligible injection site ( medial deltoid muscle ) . 18 . History axillary lymph node dissection . 19 . Patients chemotherapy radiotherapy within 28 day ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 28 day earlier .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Sexually Transmitted Diseases , Viral</keyword>
</DOC>